Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria

Hypertension Research

Volumn 34, Issue 8, 2011, Pages 935-941

  Abe, Masanori ^a   Maruyama, Noriaki ^a   Okada, Kazuyoshi ^a   Matsumoto, Shiro ^a   Matsumoto, Koichi ^a   Soma, Masayoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

aldosterone; calcium channel blocker; chronic kidney disease; diabetic nephropathy; oxidant stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; ALDOSTERONE; AMLODIPINE; AZELNIDIPINE; CREATININE; FATTY ACID BINDING PROTEIN; OLMESARTAN; RENIN;

AGED; ALBUMINURIA; ANEMIA; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG POTENTIATION; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

AGED; ALBUMINURIA; ALDOSTERONE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; AZETIDINECARBOXYLIC ACID; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; TETRAZOLES;

EID: 79961190086     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.67     Document Type: Article

References (42)

1. Japanese Society of Hypertension. Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertension Res 2009; 32: 4-107.
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Eng J Med 1993; 329: 1456-1462. (Pubitemid 23335891)
3. Brenner BM, Cooper MD, De Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med 2001; 345: 861-869.
4. Lavermann GD, Henning RH, De Jong PE, Navis G, De Zeeuw D. Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 2001; 38: 1381-1384. (Pubitemid 34193131)
5. Waeber B. Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials. J Hypertens 2006; 24: 19-27.
6. Otsu HH, Can H, Spentzos D, Nelson RG, Hanson RL, Looker HC, Knowler WC, Montroy M, Libermann TA, Karumanchi SA, Thadhani R. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007; 30: 638-643. (Pubitemid 46354346)
7. Thomas MC, Burns WC, Cooper ME. Tubular changes in early diabetic nephropathy. Adv Chronic Kid Dis 2005; 12: 177-186. (Pubitemid 40489000)
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 818-820.
9. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002; 288: 2579-2588. (Pubitemid 35386893)
10. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 2005; 28: 2728-2732. (Pubitemid 43951167)
11. Kanauchi M, Nishioka H, Hashimoto T. Oxidative DNA damage and tubulointerstitial injury in diabetic nephropathy. Nephron 2002; 91: 327-329. (Pubitemid 34621703)
12. Xu GW, Yao QH, Weng QF, Su BL, Zhang X, Xiong JH. Study of urinary 8-hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in diabetic nephropathy. J Pharm Biomed Anal 2004; 36: 101-104. (Pubitemid 39209412)
13. Shiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006; 47: 312-318.
14. Kondo N, Kiyomoto H, Yamamoto T, Miyatake A, Sun GP, Rahman M, Hitomi H, Moriwaki K, Hara T, Kimura S, Abe Y, Kohno M, Nishiyama A. Effects of calcium channel blockade on angiotensin II-induced peritubular ischemia in rats. J Pharmacol Exp Ther 2006; 316: 1047-1052. (Pubitemid 43345277)
15. Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide T, Node K. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 2007; 333: 321-326. (Pubitemid 46945471)
16. Ogawa S, Mori T, Nako K, Ito S. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens Res 2008; 31: 1147-1155.
17. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
18. Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hikawa A, Hirano N, Hirata Y, Goto A, Omata M. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 2004; 143: 23-30. (Pubitemid 38156413)
19. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Kimura K. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med 2005; 145: 125-133. (Pubitemid 40432361)
20. Goodarzi MT, Navidi AA, Rezaei M, Rezaei HB. Oxidative damage to DNA and lipids: correlation with protein glycation in patients with type 1 diabetes. J Clin Lab Anal 2010; 24: 71-76.
21. Kasai H. Analysis of a form of oxidative DNA damage 8-hydroxy-2¢- deoxyguanosine as a marker of cellular oxidative stress during carcinogenesis. Mutat Res 1997; 387: 146-163.
22. Hata I, Kaji M, Hirano S, Shigematsu Y, Tsukahara H, Mayumi M. Urinary oxidative stress markers in young patients with type 1 diabetes. Pediatr Int 2006; 48: 58-61.
23. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induc inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002; 161: 1773-1781. (Pubitemid 35265535)
24. Struthers AD, MacDonald TM. Review of aldosterone-and angiotensin II induced target organ damage and prevention. Cardiovasc Res 2004; 61: 663-670. (Pubitemid 38249465)
25. Yoshida K, Kim-Mitsuyama S, Wake R, Izumi Y, Yukimura T, Ueda M, Yoshiyama M, Iwao H. Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. Hypertens Res 2005; 28: 447-455. (Pubitemid 41007460)
26. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, Kimura S, Yukimura T, Kiyomoto H, Kohno M, Abe Y, Nishiyama A. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 2005; 16: 2906-2912. (Pubitemid 44743488)
27. Rossier MF, Lesouhaitier O, Perrier E, Bockhorn L, Chiappe A, Lalevee N. Aldosterone regulation of T-type calcium channels. J Steroid Biochem Mol Biol 2003; 85: 383-388. (Pubitemid 37011114)
28. Laleve N, Rebsamen MC, Barrere-Lemaire S, Perrier E, Nargeot J, Benitah JP, Rossier MF. Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res 2005; 67: 216-224. (Pubitemid 40943614)
29. Furukawa T, Nukada T, Namiki Y, Mayashita Y, Hatsuno K, Ueno Y, Yamakawa T, Isshiki T. Five different profiles of dihydropyridines in blocking T-type Ca2+ channel subtypes (Cav3.1 (a1G), Ca3.2 (a1H), and Ca3.3 (a1I)) expressed in Xenopus oocytes. Eur J Pharmacol 2009; 613: 100-107.
30. Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100: 342-353.
31. Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease. Hypertens Res 2009; 32: 270-275.
32. Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Ohta S, Yoshii M, Minami J, Ono H, Numabe A, Matsuoka H. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007; 30: 621-626. (Pubitemid 47278320)
33. Sugano N, Wakino S, Kanda T, Tatematsu S, Homma K, Yoshioka K, Hasegawa K, Hara Y, Suetsugu Y, Yoshizawa T, Hara Y, Utsunomiya Y, Tokudome G, Hosoya T, Saruta T, Hayashi K. T-type calcium channel blockade as a therapeutic strategy against injury in rats with subtotal nephrectomy. Kidney Int 2008; 73: 826-834. (Pubitemid 351398286)
34. Zhao D, Pothoulakis C. Rho GTPases as therapeutic targets for the treatment of inflammatory diseases. Expert Opin Ther Targets 2003; 7: 583-592. (Pubitemid 37258837)
35. Perez-Reyes E. Molecular physiology of low-voltage-activated T-type calcium channels. Physiol Rev 2003; 83: 117-161. (Pubitemid 36459879)
36. Nitta Y, Yamamoto R, Yamaguchi Y, Katsuda S, Kaku B, Taguchi T, Takabatake S, Nakahama K, Yamagisi M. Impact of long-acting calcium channel blockers on the prognosis of patients with coronary artery disease with and without chronic kidney disease: a comparison of three drugs. J Int Med Res 2010; 38: 253-265.
37. Manotham K, Tanaka T, Matsumoto M, Ohse T, Miyata T, Inagi R, Kurokawa K, Fujita T, Nangaku M. Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol 2004; 15: 1277-1288. (Pubitemid 38526009)
38. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16: 1135-1140. (Pubitemid 41710325)
39. Dzau VJ. Theodore Cooper Lecture: tissue angiotesin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-1052. (Pubitemid 32304002)
40. Nakayama S, Watada H, Mita T, Ikeda F, Shimizu T, Uchino H, Fujitani Y, Hirose Y, Kawamori R. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 2008; 31: 7-13. (Pubitemid 351325609)
41. Shibata S, Nagase M, Fujita T. Fluvastatin ameliorates podocyte injury in proteinuria rats via modulation of excessive Rho signaling. J Am Soc Nephrol 2006; 17: 754-764.
42. Agarwal R. Effects of statins on renal function. Am J Cardiol 2006; 97: 748-755. (Pubitemid 43255052)